05 Feb 2026 09:30 CET

Issuer

Zelluna ASA

Oslo, Norway, 5 February 2026 - Zelluna (OSE: ZLNA), a company pioneering
allogeneic "off-the-shelf" T-cell receptor-based natural killer (TCR-NK)
therapies for the treatment of cancer, invites to a webcast presentation of its
fourth quarter 2025 results on Thursday, 12 February 2026.

The presentation can be followed live via a webcast link available on
www.zelluna.com at 08:30 CET on Thursday, 12 February 2026. The webcast
recording will remain available on the company's website after the event, and
participants will be able to submit questions during the presentation.

The quarterly report and presentation materials will be published on the
company's website at 07:00 CET on the same day.

For further information, please see www.zelluna.com or contact:

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
(https://www.globenewswire.com/Tracker?data=Z8lLmV-
B1LwB9B24FA19vFGXbMF1uWuib96CE8rRZizu90Na0VH2EMuvz0ZT8R_M3cGZvcz7cwsWR7BQXKOGGup
zjLAZA3udqBHb-dOQPqaJliih1_RADUlCCR7Hs9ov)
Phone: +44 7720 687608

Geir Christian Melen, CFO, Zelluna ASA
Email: geir.christian.melen@zelluna.com
(mailto:geir.christian.melen@zelluna.com)
Phone: +47 913 02 965


Source

Zelluna ASA

Provider

Oslo Børs Newspoint

Company Name

ZELLUNA

ISIN

NO0013524942

Symbol

ZLNA

Market

Euronext Oslo Børs